Skip to Content

Fenoldopam Pregnancy and Breastfeeding Warnings

Fenoldopam is also known as: Corlopam

Medically reviewed by Last updated on Sep 16, 2020.

Fenoldopam Pregnancy Warnings

Animal studies have revealed evidence of maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category: B

See references

Fenoldopam Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

-According to some authorities, this drug is unlikely to adversely affect a nursing infant due to its poor oral bioavailability and short half-life.
-This drug can be administered intravenously to pediatric patients less than 1 month (at least 2 kg or full term).

See references

References for pregnancy information

  1. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.

References for breastfeeding information

  1. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.